Retail flower has halved in two years. Canadian import prices are down 28.7% from their peak even as shipment volumes climbed nearly fivefold. And on the wholesale desk, the €2/g line has already broken. In barely two years Germany has gone from the world’s most attractive medical cannabis market to its most price-competitive — and the compression that began on the pharmacy shelf is now travelling up the chain, from retail to wholesale to the Canadian export invoice. This analysis traces how far each layer has fallen — and asks where, if anywhere, the floor sits.
A Cannamonitor analysis · drawn from our German cannabis pricing dataset (2023–2026) and validated against broker data, customs statistics and market reports.
Table of Contents
Two things to know before reading further. First, this is not a demand story: German patient demand is rising fast, and the price falls are the product of structural oversupply — a sixfold jump in imports into a market already running long.
Second, the compression is market-specific, not a global condition: over the same period UK and Swiss wholesale prices held stable. Germany is deflating because Germany, uniquely, paired a large self-pay market with open import competition.
Retail flower has halved in two years — and shows no floor
German pharmacy flower has been cut roughly in half since the 2024 reform — from about €10/g before legalisation to a reconciled analyst average of €4.65/g by Q2 2026, a fall of around 52%. The signal rests on six independent series, from pharmacy dispensing ledgers to telemedicine baskets, all showing declines at annualised rates between 17% and 39%.
The best-evidenced 2026 retail level is €4–6/g, and what patients actually pay sits toward the top of that band. Cannamedical’s volume-weighted average across roughly 86,000 orders was €5.40/g, while the pharmacy wholesaler PHAGRO reported an average listing of €6.81/g. Underneath the average the whole distribution has shifted down: budget flower now changes hands at €1–2.50/g, the premium tier has slipped to €6–8/g, and legal retail has quietly undercut the illicit street benchmark of roughly €9–10/g — the threshold reform was meant to beat.
The mechanism is oversupply, not fading demand. Imports rose roughly sixfold to about 205 tonnes in 2025, landing in a market variously estimated to be 14–30% long, while the number of specialised cannabis pharmacies grew around fivefold and price-comparison platforms turned that inventory into direct, transparent competition. Demand, meanwhile, has concentrated where discounting lives: self-pay telemedicine now accounts for over 70% of prescriptions, up from roughly half before reform, and it is in this channel that discount flower reaches €1/g even as premium genetics still clear €10/g.
The commoditisation is potency-led. Measured properly — by price per 10mg of THC rather than per gram — the decline is even steeper, down about 36% year on year, as buyers cluster around cheap, high-potency product and reward little else. Nothing in the current data marks a floor: each quarter the reconciled average has stepped down again, and the structural drivers behind it — imports, pharmacy count, platform transparency — are all still intensifying.
Wholesale prices are deflating but Germany still pays a premium
Wholesale prices are also seeing significant pressure. On Spring 2026 Canadian brokerage data, German GACP flower traded from €0.60/g and EU-GMP from €1.25/g, with bands stretching to €2.50/g and €3.48/g respectively — which means the €2/g line, long treated as a psychological floor, has already broken on lower-THC GACP material rather than merely been approached.
EU-GMP flower above 20% THC is the only category showing merely modest erosion, still clearing as much as double GACP for equivalent potency. As enforcement narrows the field of compliant suppliers — tighter GACP inspections by German state authorities, compliance-driven bottlenecks at reprocessing hubs in Portugal— certification, not potency, is emerging as the last defensible pricing moat in the German chain.
The clearest picture of where the reset is heading is not on the wholesale desk but on the customs invoice. Canadian medical-flower shipments into Germany — now the single largest bilateral corridor in the trade — show volume and price decoupling with unusual clarity: buyers are taking far more kilos each quarter at a steadily falling price per kilo.
Canada -> Germany: export prices are falling as volumes climb
Quarterly Canadian medical-flower exports to Germany (HS 1211.90.10), with the weighted-average declared export price overlaid on a common euro basis.
Source: Statistics Canada, HS 1211.90.10, processed by Cannamonitor. Price = total export value ÷ total quantity; quality-flagged records excluded. Q2 2026 covers April & May only. Currency conversion: ECB quarterly average CAD per EUR.
Every number behind price depression in Germany
Between Q3 2024 and Q1 2026, export volume rose nearly fivefold — up 484% — while the weighted declared price fell 28.7% from its Q1 2025 peak of €2,507/kg to around €1,790/kg a year later. The recent plateau near €1.8/g is a mix effect rather than a true floor: the cheapest GACP material is increasingly diverted to European reprocessing hubs, leaving the direct corridor skewed toward more premium product. Germany now absorbs about 55% of all Canadian flower export value — evidence that the corridor is being repriced by competition, not shrinking.
And here is the paradox that keeps Germany strategically central: even after two years of compression, it remains the most profitable destination in the international trade. German landed prices still run about 1.6× those of peer import markets and 2.1× the reprocessing hubs, and the direction of travel is not uniform — over the same six months UK and Swiss wholesale prices rose while Germany and Australia fell. Germany is deflating from the top, not the bottom.
That leaves one open question, and it is the one operators should be modelling now. With EU-GMP wholesale closing in on €1.5/g and GACP already beneath €1/g, where does the floor actually sit — and does the compliance premium still pay for itself once the gap to GACP narrows? Poland offers a cautionary read on the demand-side comfort blanket: there, dispensed volume rose 12% even as sales fell 19%, proof that rising volumes do not protect revenue. Germany remains the market everyone wants to be in; the next phase of the reset will decide how much that access is worth.
Sources & methodology
Built on Cannamonitor’s German retail and wholesale pricing dataset (2023–2026), reconciling six independent retail series with Spring 2026 broker wholesale bands and Statistics Canada export data (HS 1211.90.10), validated against workspace market reports and company disclosures.
🔓 The full reconciliation
Six retail series on one €/g axis, the German wholesale bands by certification tier, destination benchmarks against the UK, Israel, Australia and Switzerland, and the live datasets behind every figure — all in the Germany Pricing Brief.
Stop reading the market. Start deciding.
Explore Decide → cannamonitor.com/decide